Vascepa
- Product NDC
- 52937-001
- 11-digit product format
- 529370001
- Labeler code
- 52937
- Product ID
- 52937-001_86b35fe3-d1cf-478e-849b-2ea0c87bda33
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- icosapent ethyl
- Dosage form
- CAPSULE
- Route
- ORAL
- Labeler
- Amarin Pharma Inc.
- Application
- NDA202057
- Marketing category
- NDA
- Marketing start
- 2012-10-01
- Substance
- ICOSAPENT ETHYL
- Active strength
- 1000 mg/1
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
NDC auxiliary status#
Explicit status records from FDA unfinished, excluded, and compounder auxiliary files. Absence of a row is not itself a regulatory status. Browse every current auxiliary row, including rows without a usable NDC. · Browse every captured source and parsed snapshot.
| Dataset | Scope | Product NDC | Package NDC | Code | Status | Reporting period | Source date |
|---|---|---|---|---|---|---|---|
| excluded package | package | 52937-001 | 52937-001-04 | D | Discontinued by firm | 2026-07-31 | |
| excluded package | package | 52937-001 | 52937-001-21 | D | Discontinued by firm | 2026-07-31 |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N202057-001 | VASCEPA | ICOSAPENT ETHYL | 1GM | CAPSULE / ORAL | AB | RLD, RS | 2012-07-26 |
| N202057-002 | VASCEPA | ICOSAPENT ETHYL | 500MG | CAPSULE / ORAL | AB | RLD | 2017-02-16 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| N202057-001 | AB |
| N202057-002 | AB |
Orange Book patents#
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N202057-001 | 9700537 | 2027-05-31 | U-2707 | 2020-01-10 | |
| N202057-001 | 9198892 | 2027-09-25 | U-2706 | 2020-01-10 | |
| N202057-001 | 12171738 | 2030-02-09 | U-4105 | 2025-01-23 | |
| N202057-001 | 8415335 | 2030-02-09 | U-1287 | 2013-04-17 | |
| N202057-001 | 8426399 | 2030-02-09 | U-1287 | ||
| N202057-001 | 8518929 | 2030-02-09 | U-1287 | ||
| N202057-001 | 8524698 | 2030-02-09 | U-1287 | 2013-09-11 | |
| N202057-001 | 8546372 | 2030-02-09 | U-1287 | 2013-10-01 | |
| N202057-001 | 8680144 | 2030-02-09 | U-2695 | 2020-01-06 | |
| N202057-001 | 10010517 | 2030-04-29 | U-2690 | 2020-01-06 | |
| N202057-001 | 10265287 | 2030-04-29 | U-2700 | 2020-01-06 | |
| N202057-001 | 10792267 | 2030-04-29 | U-2961 | 2020-10-16 | |
| N202057-001 | 10842766 | 2030-04-29 | U-2997 | 2020-12-11 | |
| N202057-001 | 10881632 | 2030-04-29 | U-3052 | 2021-02-04 | |
| N202057-001 | 11103477 | 2030-04-29 | U-3209 | 2021-09-21 | |
| N202057-001 | 11154526 | 2030-04-29 | U-3240 | 2021-11-08 | |
| N202057-001 | 11213504 | 2030-04-29 | U-3292 | 2022-02-03 | |
| N202057-001 | 11717504 | 2030-04-29 | U-3669 | 2023-08-18 | |
| N202057-001 | 8298554 | 2030-04-29 | Drug product | ||
| N202057-001 | 8445003 | 2030-04-29 | U-1287 | ||
| N202057-001 | 8445013 | 2030-04-29 | U-1287 | ||
| N202057-001 | 8454994 | 2030-04-29 | U-2689 | 2020-01-06 | |
| N202057-001 | 8501225 | 2030-04-29 | U-1287 | ||
| N202057-001 | 8563608 | 2030-04-29 | U-1287 | 2013-10-22 | |
| N202057-001 | 8617593 | 2030-04-29 | U-1478 | 2014-01-14 | |
| N202057-001 | 8617593 | 2030-04-29 | U-2691 | 2014-01-14 | |
| N202057-001 | 8617594 | 2030-04-29 | U-1287 | ||
| N202057-001 | 8618166 | 2030-04-29 | U-2689 | 2020-01-06 | |
| N202057-001 | 8623406 | 2030-04-29 | U-1478 | 2014-01-14 | |
| N202057-001 | 8623406 | 2030-04-29 | U-2692 | 2014-01-14 | |
| N202057-001 | 8642077 | 2030-04-29 | U-2693 | 2020-01-06 | |
| N202057-001 | 8691871 | 2030-04-29 | U-2689 | 2020-01-06 | |
| N202057-001 | 8703185 | 2030-04-29 | U-2691 | 2020-01-06 | |
| N202057-001 | 8709475 | 2030-04-29 | U-2689 | 2020-01-06 | |
| N202057-001 | 10842768 | 2030-06-15 | U-2688 | 2020-12-11 | |
| N202057-001 | 8410086 | 2030-06-15 | U-2688 | 2020-01-06 | |
| N202057-001 | 8455472 | 2030-06-15 | U-2690 | 2020-01-06 | |
| N202057-001 | 8669245 | 2030-06-15 | U-2694 | 2020-01-06 | |
| N202057-001 | 8710041 | 2030-06-15 | U-2690 | 2020-01-06 | |
| N202057-001 | 10278935 | 2033-06-28 | U-2701 | 2020-01-06 | |
| N202057-001 | 10278936 | 2033-06-28 | U-2702 | 2020-01-06 | |
| N202057-001 | 10278937 | 2033-06-28 | U-2703 | 2020-01-06 | |
| N202057-001 | 10383840 | 2033-06-28 | U-2704 | 2020-01-06 | |
| N202057-001 | 10555924 | 2033-06-28 | U-2743 | 2020-02-26 | |
| N202057-001 | 10555925 | 2033-06-28 | U-2744 | 2020-02-26 | |
| N202057-001 | 10568861 | 2033-06-28 | U-2756 | 2020-03-20 | |
| N202057-001 | 10576054 | 2033-06-28 | U-2762 | 2020-03-27 | |
| N202057-001 | 10668042 | 2033-06-28 | U-2841 | 2020-06-26 | |
| N202057-001 | 10786478 | 2033-06-28 | U-2959 | 2020-10-16 | |
| N202057-001 | 10786478 | 2033-06-28 | U-2960 | 2020-10-16 | |
| N202057-001 | 10792270 | 2033-06-28 | U-2962 | 2020-10-16 | |
| N202057-001 | 10894028 | 2033-06-28 | U-3053 | 2021-02-04 | |
| N202057-001 | 11000499 | 2033-06-28 | U-3126 | 2021-06-10 | |
| N202057-001 | 11116742 | 2033-06-28 | U-3221 | 2021-10-08 | |
| N202057-001 | 11298333 | 2033-06-28 | U-3358 | 2022-05-11 | |
| N202057-001 | 11369582 | 2033-06-28 | U-2841 | 2022-07-28 | |
| N202057-001 | 9603826 | 2033-06-28 | U-2696 | 2020-01-06 | |
| N202057-001 | 9610272 | 2033-06-28 | U-2697 | 2020-01-06 | |
| N202057-001 | 9623001 | 2033-06-28 | U-2698 | 2020-01-06 | |
| N202057-001 | 9693984 | 2033-06-28 | U-2697 | 2020-01-06 | |
| N202057-001 | 9693985 | 2033-06-28 | U-2696 | 2020-01-06 | |
| N202057-001 | 9693986 | 2033-06-28 | U-2698 | 2020-01-06 | |
| N202057-001 | 9918954 | 2033-06-28 | U-2699 | 2020-01-06 | |
| N202057-002 | 9700537 | 2027-05-31 | U-2707 | 2020-01-10 | |
| N202057-002 | 9198892 | 2027-09-25 | U-2706 | 2020-01-10 | |
| N202057-002 | 12171738 | 2030-02-09 | U-4105 | 2025-01-23 | |
| N202057-002 | 8399446 | 2030-02-09 | U-1287 | 2017-06-26 | |
| N202057-002 | 8415335 | 2030-02-09 | U-1287 | 2017-06-26 | |
| N202057-002 | 8426399 | 2030-02-09 | U-1287 | 2017-06-26 | |
| N202057-002 | 8518929 | 2030-02-09 | U-1287 | 2017-06-26 | |
| N202057-002 | 8524698 | 2030-02-09 | U-1287 | 2017-06-26 | |
| N202057-002 | 8546372 | 2030-02-09 | U-1287 | 2017-06-26 | |
| N202057-002 | 8680144 | 2030-02-09 | U-2695 | 2020-01-06 | |
| N202057-002 | 10010517 | 2030-04-29 | U-2690 | 2020-01-06 | |
| N202057-002 | 10265287 | 2030-04-29 | U-2700 | 2020-01-06 | |
| N202057-002 | 10792267 | 2030-04-29 | U-2961 | 2020-10-16 | |
| N202057-002 | 10842766 | 2030-04-29 | U-2997 | 2020-12-11 | |
| N202057-002 | 10881632 | 2030-04-29 | U-3052 | 2021-02-04 | |
| N202057-002 | 11103477 | 2030-04-29 | U-3209 | 2021-09-21 | |
| N202057-002 | 11154526 | 2030-04-29 | U-3240 | 2021-11-08 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | VASCEPA | 1GM | CAPSULE / ORAL | AB | RLD, RS | 2012-07-26 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N202057-002 | VASCEPA | 500MG | CAPSULE / ORAL | AB | RLD | 2017-02-16 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | AB | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N202057-002 | AB | 1 | a50c72e98297… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 9700537 | 2027-05-31 | U-2707 | 2020-01-10 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 9198892 | 2027-09-25 | U-2706 | 2020-01-10 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 12171738 | 2030-02-09 | U-4105 | 2025-01-23 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8415335 | 2030-02-09 | U-1287 | 2013-04-17 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8426399 | 2030-02-09 | U-1287 | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8518929 | 2030-02-09 | U-1287 | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8524698 | 2030-02-09 | U-1287 | 2013-09-11 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8546372 | 2030-02-09 | U-1287 | 2013-10-01 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8680144 | 2030-02-09 | U-2695 | 2020-01-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 10010517 | 2030-04-29 | U-2690 | 2020-01-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 10265287 | 2030-04-29 | U-2700 | 2020-01-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 10792267 | 2030-04-29 | U-2961 | 2020-10-16 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 10842766 | 2030-04-29 | U-2997 | 2020-12-11 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 10881632 | 2030-04-29 | U-3052 | 2021-02-04 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 11103477 | 2030-04-29 | U-3209 | 2021-09-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 11154526 | 2030-04-29 | U-3240 | 2021-11-08 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 11213504 | 2030-04-29 | U-3292 | 2022-02-03 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 11717504 | 2030-04-29 | U-3669 | 2023-08-18 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8298554 | 2030-04-29 | Drug product | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8445003 | 2030-04-29 | U-1287 | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8445013 | 2030-04-29 | U-1287 | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8454994 | 2030-04-29 | U-2689 | 2020-01-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8501225 | 2030-04-29 | U-1287 | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8563608 | 2030-04-29 | U-1287 | 2013-10-22 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8617593 | 2030-04-29 | U-1478 | 2014-01-14 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8617593 | 2030-04-29 | U-2691 | 2014-01-14 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8617594 | 2030-04-29 | U-1287 | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8618166 | 2030-04-29 | U-2689 | 2020-01-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8623406 | 2030-04-29 | U-2692 | 2014-01-14 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8623406 | 2030-04-29 | U-1478 | 2014-01-14 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8642077 | 2030-04-29 | U-2693 | 2020-01-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8691871 | 2030-04-29 | U-2689 | 2020-01-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8703185 | 2030-04-29 | U-2691 | 2020-01-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8709475 | 2030-04-29 | U-2689 | 2020-01-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 10842768 | 2030-06-15 | U-2688 | 2020-12-11 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8410086 | 2030-06-15 | U-2688 | 2020-01-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8455472 | 2030-06-15 | U-2690 | 2020-01-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8669245 | 2030-06-15 | U-2694 | 2020-01-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 8710041 | 2030-06-15 | U-2690 | 2020-01-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N202057-001 | 10278935 | 2033-06-28 | U-2701 | 2020-01-06 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Vascepa | ICOSAPENT ETHYL | Bryant Ranch Prepack | d245ddab-d81b-44bd-90d7-0e4d446d9bf5 | 2026-04-07 | Warnings, Adverse reactions | 202057 NDA202057 |
| Vascepa | ICOSAPENT ETHYL | Amarin Pharma Inc. | 9c1a2828-1583-4414-ab22-a60480e8e508 | 2026-03-23 | Warnings, Adverse reactions | 202057 NDA202057 52937-001 |
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Vascepa
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| ICOSAPENT ETHYL | 1000 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 6GC8A4PAYH | Internal UNII lookup |
Harmonized RxCUI identifiers#
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 9c1a2828-1583-4414-ab22-a60480e8e508 | Available on FDA.report |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| f6766515-27b8-72de-2010-167151236ace | Product name | 7 | 20251021 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 52937-001-04 | Vascepa | 4 in 1 BOTTLE | CAPSULE | 4 | 21 | |
| 52937-001-20 | Vascepa | 120 in 1 BOTTLE | CAPSULE | 120 | 21 | |
| 52937-001-21 | Vascepa | 120 in 1 BOTTLE | CAPSULE | 120 | 21 |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 52937-001-20 | EA - Each | 52937-001 | e251bdc4-2fb9-442b-a34c-598eadb6ea4f | 1 | 2013-02-13 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| icosapent ethyl | ACTIVE INGREDIENT | 6GC8A4PAYH | VASCEPA (ICOSAPENT ETHYL) CAPSULE [AMARIN PHARMA INC.] | 10 | |
| icosapent | ACTIVE MOIETY | AAN7QOV9EA | VASCEPA (ICOSAPENT ETHYL) CAPSULE [AMARIN PHARMA INC.] | 10 | |
| Gelatin | INACTIVE INGREDIENT | 2G86QN327L | VASCEPA (ICOSAPENT ETHYL) CAPSULE [AMARIN PHARMA INC.] | 10 | |
| Glycerin | INACTIVE INGREDIENT | PDC6A3C0OX | VASCEPA (ICOSAPENT ETHYL) CAPSULE [AMARIN PHARMA INC.] | 10 | |
| Maltitol | INACTIVE INGREDIENT | D65DG142WK | VASCEPA (ICOSAPENT ETHYL) CAPSULE [AMARIN PHARMA INC.] | 10 | |
| Sorbitol | INACTIVE INGREDIENT | 506T60A25R | VASCEPA (ICOSAPENT ETHYL) CAPSULE [AMARIN PHARMA INC.] | 10 | |
| Tocopherol | INACTIVE INGREDIENT | R0ZB2556P8 | VASCEPA (ICOSAPENT ETHYL) CAPSULE [AMARIN PHARMA INC.] | 10 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | VASCEPA (ICOSAPENT ETHYL) CAPSULE [AMARIN PHARMA INC.] | 10 |
DailyMed Dashboard NDC Coverage#
DailyMed RxNorm Mappings#
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|---|
| 52937-001-04 | 52937000104 | 4 CAPSULE in 1 BOTTLE (52937-001-04) | 4 capsule | 2012-10-01 | 0000-00-00 | No | No | Current |
| 52937-001-20 | 52937000120 | 120 CAPSULE in 1 BOTTLE (52937-001-20) | 120 capsule | 2012-10-01 | 0000-00-00 | No | No | Current |
| 52937-001-21 | 52937000121 | 120 CAPSULE in 1 BOTTLE (52937-001-21) | 120 capsule | 2012-10-01 | 0000-00-00 | No | No | Current |